989 related articles for article (PubMed ID: 29174294)
1. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
2. Peptide hormone ghrelin enhances neuronal excitability by inhibition of Kv7/KCNQ channels.
Shi L; Bian X; Qu Z; Ma Z; Zhou Y; Wang K; Jiang H; Xie J
Nat Commun; 2013; 4():1435. PubMed ID: 23385580
[TBL] [Abstract][Full Text] [Related]
3. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
4. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
5. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
Fletcher EJR; Moon LDF; Duty S
BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
[TBL] [Abstract][Full Text] [Related]
6. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
[TBL] [Abstract][Full Text] [Related]
7. Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.
Gui ZH; Liu J; Wang Y; Ali U; Wang T; Chen L
Chin J Physiol; 2011 Apr; 54(2):96-104. PubMed ID: 21789890
[TBL] [Abstract][Full Text] [Related]
8. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
Hansen HH; Ebbesen C; Mathiesen C; Weikop P; Rønn LC; Waroux O; Scuvée-Moreau J; Seutin V; Mikkelsen JD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1006-19. PubMed ID: 16775195
[TBL] [Abstract][Full Text] [Related]
9. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Sleeman IJ; Boshoff EL; Duty S
Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
[TBL] [Abstract][Full Text] [Related]
12. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
13. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
15. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
[TBL] [Abstract][Full Text] [Related]
16. Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
Sarookhani MR; Haghdoost-Yazdi H; Sarbazi-Golezari A; Babayan-Tazehkand A; Rastgoo N
Behav Pharmacol; 2018 Jun; 29(4):336-343. PubMed ID: 29239973
[TBL] [Abstract][Full Text] [Related]
17. Changes in SK channel expression in the basal ganglia after partial nigrostriatal dopamine lesions in rats: Functional consequences.
Mourre C; Manrique C; Camon J; Aidi-Knani S; Deltheil T; Turle-Lorenzo N; Guiraudie-Capraz G; Amalric M
Neuropharmacology; 2017 Feb; 113(Pt A):519-532. PubMed ID: 27825825
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
[TBL] [Abstract][Full Text] [Related]
19. Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
Lin L; Yan M; Wu B; Lin R; Zheng Z
Brain Res Bull; 2018 Sep; 142():338-343. PubMed ID: 30172737
[TBL] [Abstract][Full Text] [Related]
20. Experimental change on dopaminergic neurons in striatum of Parkinson disease rats.
Chen XY; Li J; Qi WQ; Shen SH
Histol Histopathol; 2007 Oct; 22(10):1085-90. PubMed ID: 17616935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]